GlobeNewswire·Nov 6, 2026, 8:15 AM ET

CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates

CG Oncology reported Q3 2026 financial results & provided business updates on November 6, 2026.
PIVOT-006 Phase 3 topline data for cretostimogene in intermediate-risk & high-grade Ta NMIBC is expected in November 2026.
12-month data for BOND-003 Cohort P & CORE-008 Cohort CX is anticipated in December 2026.
BLA completion for BCG-unresponsive NMIBC is expected in Q4 2026.
Isabel Kalofonos joined as Chief Commercial Officer in October 2026 with over 20 years of life-science experience.
Cash, cash equivalents, & marketable securities totaled $984.5 million as of September 30, 2026.
The company's cash position is sufficient to fund operations through 2029.
R&D expenses were $39.2 million in Q3 2026, driven by increased clinical trial & compensation costs.
G&A expenses were $23.0 million in Q3 2026, down from $23.3 million the prior year due to reduced professional fees.
Net loss was $56.9 million ($0.64 per share) for Q3 2026, compared to $43.8 million ($0.57 per share) in the prior year.
Cretostimogene has received FDA Fast Track & Breakthrough Therapy designations for BCG-unresponsive NMIBC.
The cretostimogene development program includes more than 700 patients across Phase 3 trials BOND-003 & PIVOT-006.
An Expanded Access Program for cretostimogene is active in North America for eligible BCG-unresponsive patients.